Portola Announces Closing of Initial Public Offering and Over-Allotment Option Exercise
29 Mai 2013 - 12:31AM
Marketwired
Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) announced today the
closing of its initial public offering of 9,686,171 shares of its
common stock at a price to the public of $14.50 per share. All of
the 9,686,171 shares are being offered by Portola and include
1,263,413 shares issued pursuant to the over-allotment option
granted to the underwriters, which was exercised in full.
Morgan Stanley and Credit Suisse acted as the joint book-running
managers for the offering. Cowen and Company, William Blair and
Sanford C. Bernstein acted as co-managers. Copies of the prospectus
relating to this offering may be obtained from the offices of
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, New York 10014, or by email at
prospectus@morganstanley.com or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, One Madison Avenue, New York, NY
10010, by email at newyork.prospectus@credit-suisse.com or by
toll-free call to (800) 221-1037.
A registration statement relating to these securities has been
filed with, and was declared effective by, the Securities and
Exchange Commission on May 21, 2013. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Portola Pharmaceuticals, Inc.
Portola is a biopharmaceutical company focused on the
development and commercialization of novel therapeutics in the
areas of thrombosis, other hematologic disorders and inflammation
for patients who currently have limited or no approved treatment
options. Portola's current development-stage portfolio consists of
three compounds discovered through its internal research efforts
and one discovered by Portola scientists during their time at a
prior company.
Portola's two lead programs address significant unmet medical
needs in the area of thrombosis, or blood clots. Portola's lead
compound, betrixaban, is a novel oral once-daily inhibitor of
Factor Xa in Phase 3 development for extended duration prophylaxis,
or preventive treatment, of a form of thrombosis known as venous
thromboembolism, or VTE, in acute medically ill patients.
Currently, there is no anticoagulant approved for extended duration
VTE prophylaxis in this population.
Portola's second lead development candidate, PRT4445, is a
recombinant protein designed to reverse the anticoagulant activity
in patients treated with a Factor Xa inhibitor who suffer an
uncontrolled bleeding episode or undergo emergency surgery. Portola
has entered into a collaboration agreement with Bristol-Myers
Squibb Company and Pfizer Inc. and a collaboration agreement with
Bayer Pharma AG and Janssen Pharmaceuticals, Inc. to study PRT4445
with Eliquis® and XARELTO®, respectively, in Portola's Phase 2
studies. Portola retains full, worldwide commercial rights with
respect to PRT4445.
Portola's third product candidate, PRT2070, is an orally
available kinase inhibitor being developed for hematologic, or
blood, cancers and inflammatory disorders. PRT2070 inhibits spleen
tyrosine kinase, or Syk, and janus kinases, or JAK, enzymes that
regulate important signaling pathways. Subject to regulatory
approval, Portola plans to initiate a Phase 1/2 clinical study of
PRT2070 in 2013 in patients with B-cell hematologic cancers who
have failed or relapsed on existing marketed therapies or products
in development, including patients with identified mutations.
Portola's fourth program, PRT2607 and other highly selective Syk
inhibitors, is partnered with Biogen Idec Inc.
Contacts: Mardi Dier CFO Portola Pharmaceuticals Email
Contact Paul Laland BrewLife Email Contact 415.946.1071
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024